Patents by Inventor Jean X. JIANG

Jean X. JIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, AND JOINT AND TENDON DISORDERS
    Publication number: 20240076371
    Abstract: Disclosed herein are antibodies useful that bind to connexin 43 hemichannels to inhibit or block channel opening. Also disclosed herein are methods for detecting or treating osteoarthritis, rheumatoid arthritis, and tendon disorders and injuries with antibodies that inhibit or block Cx43 hemichannel opening.
    Type: Application
    Filed: January 13, 2022
    Publication date: March 7, 2024
    Inventors: Jean X. Jiang, Manuel A. Riquelme, sumin Gu, Rui Hua
  • Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel
    Patent number: 11912758
    Abstract: Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: February 27, 2024
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jean X. Jiang, Zhiqiang An, Ningyan Zhang, Wei Xiong, Manuel A. Riquelme, Sumin Gu, Naomi Ledene Sayre
  • Method of treating osteoarthritis by administering an anti-connexin 43 antibody
    Patent number: 11912762
    Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: February 27, 2024
    Assignee: Board of Regents of the University of Texas System
    Inventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu
  • SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS
    Publication number: 20230322782
    Abstract: Certain embodiments are directed to the use of chemical compounds that inhibit migration and growth of cancer cells.
    Type: Application
    Filed: May 29, 2023
    Publication date: October 12, 2023
    Inventor: Jean X. Jiang
  • Small molecules for the treatment of primary cancer and cancer metastasis
    Patent number: 11680067
    Abstract: Certain embodiments are directed to adenosine receptor antagonists that inhibit migration and growth of cancer cells.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: June 20, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventor: Jean X. Jiang
  • Small molecules for the treatment of autoimmune disorders
    Patent number: 11400096
    Abstract: Certain embodiments are directed to methods of treating autoimmune disorders by administering P2 purnergic receptor antagonist and/or adenosine receptor antagonists. The P2 purnergic receptor antagonist being chemical analogs of adenosine receptor antagonist 8-Ethoxy-9-ethyl-9H-purin-6-amine. The adenosine receptor antagonists being chemical analogs of the non-hydrolysable ATP analog adenosine 5?[?-thio]triphosphate (ATP?S). Certain embodiments are directed to the use of the chemical analogs to modulate IL-17 activity.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: August 2, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventor: Jean X. Jiang
  • Compositions and Methods for Targeting Connexin Hemichannels
    Publication number: 20220169721
    Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 2, 2022
    Inventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu
  • CX43 hemichannel antibodies and methods of use
    Patent number: 11208479
    Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: December 28, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu
  • SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
    Publication number: 20210361660
    Abstract: Certain embodiments are directed to methods of treating autoimmune disorders by administering P2 purinergic receptor antagonist and/or adenosine receptor antagonists.
    Type: Application
    Filed: October 19, 2018
    Publication date: November 25, 2021
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Jean X. JIANG
  • CONNEXIN (CX) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
    Publication number: 20210253680
    Abstract: Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening arc provided.
    Type: Application
    Filed: January 11, 2021
    Publication date: August 19, 2021
    Inventors: Jean X. Jiang, Zhiqiang An, Ningyan Zhang, Wei Xiong, Manuel A. Riquelme, Sumin Gu, Naomi Ledene Sayre
  • Compositions And Methods For Targeting Connexin Hemichannels
    Publication number: 20210238278
    Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.
    Type: Application
    Filed: April 19, 2021
    Publication date: August 5, 2021
    Inventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu
  • Small Molecules for the Treatment of Primary Cancer and Cancer Metastasis
    Publication number: 20210206769
    Abstract: Certain embodiments are directed to adenosine receptor antagonists that inhibit migration and growth of cancer cells.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 8, 2021
    Inventor: Jean X. Jiang
  • Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
    Patent number: 10889637
    Abstract: Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: January 12, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jean X. Jiang, Zhiqiang An, Ningyan Zhang, Wei Xiong, Manuel A. Riquelme, Sumin Gu, Naomi Ledene Sayre
  • Compositions And Methods For Targeting Connexin Hemichannels
    Publication number: 20200231669
    Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 23, 2020
    Inventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu
  • Antibodies to connexin 43 (Cx43) hemichannels and methods of use thereof to inhibit Cx43 hemichannel opening
    Patent number: 10633442
    Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 28, 2020
    Assignee: Board of Regents of the University of Texas System
    Inventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu
  • CONNEXIN (CX) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
    Publication number: 20190359696
    Abstract: Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.
    Type: Application
    Filed: February 27, 2017
    Publication date: November 28, 2019
    Inventors: Jean X. Jiang, Zhiqiang An, Ningyan Zhang, Wei Xiong, Manuel A. Riquelme, Sumin Gu, Naomi Ledene Sayre
  • SMALL MOLECULES FOR THE TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS
    Publication number: 20190169190
    Abstract: Certain embodiments are directed to non-hydrolysable ATP analogs and adenosine receptor antagonists that inhibit migration and growth of cancer cells.
    Type: Application
    Filed: February 4, 2019
    Publication date: June 6, 2019
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Jean X JIANG
  • Small molecules for the treatment of primary cancer and cancer metastasis
    Patent number: 10214529
    Abstract: Certain embodiments and compounds are of the class of non-hydrolysable ATP analogs and adenosine receptor antagonists, useful for inhibiting the migration and growth of cancer cells.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: February 26, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Jean X. Jiang
  • Methods for Treating Inflammatory Disorders or Cancer Metastasis by Administering Antibodies to Connexin 43 (CX43) Hemichannels
    Publication number: 20180179278
    Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 28, 2018
    Inventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu
  • Methods for treating inflammatory disorders or cancer metastasis by administering antibodies to connexin 43 (Cx43) hemichannels
    Patent number: 9914775
    Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: March 13, 2018
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu